ORIC Pharmaceuticals
Clinical trials sponsored by ORIC Pharmaceuticals, explained in plain language.
A clinical-stage biopharmaceutical company developing therapies to overcome resistance mechanisms in cancer.
Not investment advice. Company information is shown for context only. Clinical trials frequently fail.
Advertising disclosure. Links marked "(ad)" go to partners we have a commercial relationship with, either a broker where you can trade or a stock-research service, and we may earn a commission if you open an account or subscribe. This never affects what is shown here.
Upcoming readouts
Trials from this sponsor expected to report results within the next 12 months.
- Can a daily pill target hard-to-treat cancers with EGFR or HER2 mutations? Results expected Sep 2026 (estimated)
- New drug combo targets tough lung cancer mutation Results expected Dec 2026 (estimated)
- New drug ORIC-944 targets Hard-to-Treat prostate cancer Results expected Jun 2027 (estimated)
-
Can a daily pill target hard-to-treat cancers with EGFR or HER2 mutations?
Disease control Recruiting nowThis trial tests an experimental oral drug called ORIC-114 in people with advanced solid tumors that have specific changes in the EGFR or HER2 genes. The study has two parts: first, finding a safe and effective dose, and second, seeing how well the drug works alone or with chemot…
Phase 1/2 • Sponsor: ORIC Pharmaceuticals • Aim: Disease control
Last updated Sep 06, 2026 00:00 UTC
-
Can a Two-Drug attack stall resistant prostate cancer?
Disease control Recruiting nowThis phase 3 trial is testing whether adding an experimental drug called rinzimetostat to the standard drug darolutamide can slow the progression of metastatic castration-resistant prostate cancer better than current treatments. The study enrolls men whose cancer has worsened aft…
Phase 3 • Sponsor: ORIC Pharmaceuticals • Aim: Disease control
Last updated Sep 05, 2026 00:00 UTC
-
New drug ORIC-944 targets Hard-to-Treat prostate cancer
Disease control Recruiting nowThis trial investigates a new oral drug called ORIC-944, given alone or combined with standard hormone therapies, for men with metastatic prostate cancer that has spread beyond the prostate. The study aims to find the safest dose and check for early signs that the drug can contro…
Phase 1 • Sponsor: ORIC Pharmaceuticals • Aim: Disease control
Last updated Jul 11, 2026 00:00 UTC
-
New drug combo targets tough lung cancer mutation
Disease control Recruiting nowThis early-stage trial tests a new oral drug called ORIC-114 combined with an injectable drug, amivantamab, in people with advanced lung cancer that has a specific genetic change (EGFR exon20 insertion). The study aims to find the safest dose and see if the combination shrinks tu…
Phase 1 • Sponsor: ORIC Pharmaceuticals • Aim: Disease control
Last updated Jun 27, 2026 12:23 UTC